Katarina Luptakova

Xilio Therapeutics (United States) — United States

Medicine · Health Sciences

16h-index1.7kcitations108works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(47), Protein Degradation and Inhibitors(16), Glycosylation and Glycoproteins Research(15), Acute Myeloid Leukemia Research(14), Immunotherapy and Immune Responses(14)

Publications108 total

1315 Plasma tumor mutational burden (pTMB) enriched for response to vilastobart in combination with atezolizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
2025Open Access
Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.
Journal of Clinical Oncology·2025· 1 cited
1455 Phase 1 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors
2024Open Access
Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.
Journal of Clinical Oncology·2024· 1 cited
133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Immuno-Oncology Technology·2023Open Access
611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1
Regular and Young Investigator Award Abstracts·2023· 3 citedOpen Access
A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors.
Journal of Clinical Oncology·2023· 2 cited
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
Journal of Clinical Oncology·2023
Supplementary Figure Legends from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
Data from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
Supplementary Figure 2 from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
Data from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
Supplementary Figure Legends from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
Supplementary Figure 1 from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
Supplementary Figure 2 from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
Supplementary Figure 1 from MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
2023Open Access
A first-in-human, multicenter, phase 1/2, open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solid tumors.
Journal of Clinical Oncology·2022· 4 cited
Poster: MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial
Clinical Lymphoma Myeloma & Leukemia·2021· 1 cited
Poster: MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study
Clinical Lymphoma Myeloma & Leukemia·2021· 2 cited
Poster: MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Clinical Lymphoma Myeloma & Leukemia·2021
page 1 of 6Next →

Frequent Co-authors

Jacalyn Rosenblatt(17), David Avigan(17), Donald Küfe(15), Robin Joyce(14), Jon Arnason(14), Dina Stroopinsky(14), James D. Levine(12), Paul G. Richardson(9), Heidi Mills(9), Richard M. Stone(8), Lynne Uhl(8), Baldev Vasir(8), Poorvi Somaiya(8), Kenneth C. Anderson(7), Vassiliki A. Boussiotis(7), Ilene Galinsky(7), John Mascarenhas(7), Gozde Colak(7), Srđan Verstovšek(7), Salvia Jain(6)